Jubilant Ingrevia Limited (JUBLINGREA.NS)
INR 800.95
(-4.21%)
INR 800.95
(-4.21%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 47.31 Billion INR | 11.11% |
| 2022 | 42.58 Billion INR | 12.16% |
| 2021 | 37.97 Billion INR | 12.39% |
| 2020 | 33.78 Billion INR | 6756942.0% |
| 2019 | 500 Thousand INR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 48.41 Billion INR | 0.0% |
| 2024 Q1 | - INR | -100.0% |
| 2023 FY | 47.31 Billion INR | 11.11% |
| 2023 Q4 | 47.31 Billion INR | 0.0% |
| 2023 Q2 | 44.7 Billion INR | 0.0% |
| 2023 Q1 | - INR | -100.0% |
| 2023 Q3 | - INR | -100.0% |
| 2022 Q2 | 41.05 Billion INR | 0.0% |
| 2022 Q1 | - INR | -100.0% |
| 2022 Q3 | - INR | -100.0% |
| 2022 FY | 42.58 Billion INR | 12.16% |
| 2022 Q4 | 42.58 Billion INR | 0.0% |
| 2021 Q1 | - INR | -100.0% |
| 2021 FY | 37.97 Billion INR | 12.39% |
| 2021 Q4 | 37.97 Billion INR | 0.0% |
| 2021 Q3 | - INR | -100.0% |
| 2021 Q2 | 36.17 Billion INR | 0.0% |
| 2020 FY | 33.78 Billion INR | 6756942.0% |
| 2020 Q4 | 33.78 Billion INR | 6756942.0% |
| 2020 Q3 | 500 Thousand INR | 0.0% |
| 2019 FY | 500 Thousand INR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Biocon Limited | 560.7 Billion INR | 91.561% |
| Blue Jet Healthcare Limited | 10.58 Billion INR | -346.891% |
| Concord Biotech Limited | 17 Billion INR | -178.231% |
| Dishman Carbogen Amcis Limited | 95.81 Billion INR | 50.614% |
| Lyka Labs Limited | 1.56 Billion INR | -2919.245% |
| Panacea Biotec Limited | 12.4 Billion INR | -281.395% |
| Piramal Pharma Limited | 153.11 Billion INR | 69.096% |
| SMS Lifesciences India Limited | 3.9 Billion INR | -1111.692% |
| Supriya Lifescience Limited | 9.21 Billion INR | -413.645% |
| Syngene International Limited | 61.51 Billion INR | 23.079% |
| TAKE Solutions Limited | 881.05 Million INR | -5270.739% |
| Zota Health Care Limited | 2.28 Billion INR | -1972.404% |